Literature DB >> 23408186

Metastatic squamous cell carcinoma to the brain: an unrecognized pattern of distant spread in patients with HPV-related head and neck cancer.

J Ruzevick1, A Olivi, W H Westra.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is notorious for local recurrence and metastatic spread to regional lymph nodes. Distant spread is uncommon, and brain involvement is rare. Over the past decade there has been a rising incidence of HPV-related HNSCC, but it is not known if this escalation has had any impact on trends relating to brain involvement. Cases of metastatic squamous cell carcinoma (SCC) to the brain were identified from a computerized search of the surgical pathology files of The Johns Hopkins Hospital between 1985 and 2012. The medical records were reviewed to document primary site of tumor origin, treatment, and patient outcome. P16 immunohistochemistry and HPV in situ hybridization were performed on those metastases arising from the head and neck. Of the 38 metastatic SCCs, 7 (18 %) originated in the head and neck. HPV-16 was detected in 4 (57 %) of the metastatic HNSCCs. All 4 HPV-positive metastases were from oropharyngeal primaries. The time from treatment of the primary to development of the brain metastasis ranged from 19 to 57 months (mean, 45). Following aggressive treatment (surgery and radiation), two patients died of disease progression (7 and 34 months), and two are alive with recurrent brain metastases (4 and 10 months). Although HPV positivity is regarded as a favorable prognostic indicator, it does not safeguard from spread to the brain. In our experience, just over half of the HNSCCs that metastasized to the brain were HPV-related. The potential for developing a brain metastasis long after curative therapy argues for extended patient follow-up. The development of a brain metastasis is an ominous finding signaling rapid clinical deterioration.

Entities:  

Mesh:

Year:  2013        PMID: 23408186      PMCID: PMC3630253          DOI: 10.1007/s11060-013-1075-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma.

Authors:  Shahnaz Begum; Dengfeng Cao; Maura Gillison; Marianna Zahurak; William H Westra
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Epidemiology of head and neck cancer in the United States.

Authors:  Louise Davies; H Gilbert Welch
Journal:  Otolaryngol Head Neck Surg       Date:  2006-09       Impact factor: 3.497

3.  Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.

Authors:  J G Spector; D G Sessions; B H Haughey; K S Chao; J Simpson; S El Mofty; C A Perez
Journal:  Laryngoscope       Date:  2001-06       Impact factor: 3.325

4.  Patterns of spread of distant metastases in head and neck cancer.

Authors:  J C Probert; R W Thompson; M A Bagshaw
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

5.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors:  M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

6.  Intracranial metastases in patients with squamous cell carcinoma of the head and neck.

Authors:  R de Bree; D M Mehta; G B Snow; J J Quak
Journal:  Otolaryngol Head Neck Surg       Date:  2001-02       Impact factor: 3.497

7.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

Authors:  Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri
Journal:  J Clin Oncol       Date:  2006-01-09       Impact factor: 44.544

8.  HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?

Authors:  Susan Müller; Fadlo R Khuri; Scott A Kono; Jonathan J Beitler; Dong M Shin; Nabil F Saba
Journal:  Head Neck Pathol       Date:  2012-04-15

Review 9.  Management of advanced stage squamous cell carcinoma of the head and neck.

Authors:  A A Forastiere
Journal:  Am J Med Sci       Date:  1986-06       Impact factor: 2.378

10.  Distant metastases from head and neck cancer.

Authors:  R J Papac
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

View more
  27 in total

1.  Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study.

Authors:  Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-29       Impact factor: 2.503

2.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

3.  Orbital mass as first presentation of metastatic p16-positive oropharyngeal squamous cell carcinoma.

Authors:  J Corbett; D Wilke; J Trites; N Lamond
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

4.  Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.

Authors:  Theresa Guo; Jesse R Qualliotine; Patrick K Ha; Joseph A Califano; Young Kim; John R Saunders; Ray G Blanco; Gypsyamber D'Souza; Zhe Zhang; Christine H Chung; Ana Kiess; Christine G Gourin; Wayne Koch; Jeremy D Richmon; Nishant Agrawal; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2015-03-17       Impact factor: 6.860

5.  Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.

Authors:  Justin A Bishop; Elizabeth A Montgomery; William H Westra
Journal:  Am J Surg Pathol       Date:  2014-02       Impact factor: 6.394

6.  Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases.

Authors:  Joseph D Coppock; Anne M Mills; Edward B Stelow
Journal:  Head Neck Pathol       Date:  2020-06-20

7.  Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.

Authors:  Noriaki Tanaka; Ameeta A Patel; Jiping Wang; Mitchell J Frederick; Nene N Kalu; Mei Zhao; Alison L Fitzgerald; Tong-xin Xie; Natalie L Silver; Carlos Caulin; Ge Zhou; Heath D Skinner; Faye M Johnson; Jeffrey N Myers; Abdullah A Osman
Journal:  Clin Cancer Res       Date:  2015-06-29       Impact factor: 12.531

8.  Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes.

Authors:  P Sinha; W T Thorstad; B Nussenbaum; B H Haughey; D R Adkins; D Kallogjeri; J S Lewis
Journal:  Oral Oncol       Date:  2013-11-06       Impact factor: 5.337

9.  The Fidelity of p16 Staining as a Surrogate Marker of Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node Metastases: Implications for HPV Testing Protocols.

Authors:  Brittany J Holmes; Zahra Maleki; William H Westra
Journal:  Acta Cytol       Date:  2015-03-10       Impact factor: 2.319

10.  Detection of human papillomavirus (HPV) in clinical samples: evolving methods and strategies for the accurate determination of HPV status of head and neck carcinomas.

Authors:  William H Westra
Journal:  Oral Oncol       Date:  2014-06-02       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.